Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

302 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.
Strategies for Management of Antiretroviral Therapy (SMART) Study Group; Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, Neaton JD, Neuhaus J, Phillips AN. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, et al. Among authors: neaton jd. J Infect Dis. 2008 Apr 15;197(8):1145-55. doi: 10.1086/529523. J Infect Dis. 2008. PMID: 18476293 Clinical Trial.
Reply.
Emery S, Lane HC, Neaton JD. Emery S, et al. Among authors: neaton jd. J Infect Dis. 2000 Jan;183(4):680. doi: 10.1086/318546. J Infect Dis. 2000. PMID: 11171000 No abstract available.
Grade 4 events are as important as AIDS events in the era of HAART.
Reisler RB, Han C, Burman WJ, Tedaldi EM, Neaton JD. Reisler RB, et al. Among authors: neaton jd. J Acquir Immune Defic Syndr. 2003 Dec 1;34(4):379-86. doi: 10.1097/00126334-200312010-00004. J Acquir Immune Defic Syndr. 2003. PMID: 14615655
CD4(+) cell count increase predicts clinical benefits in patients with advanced HIV disease and persistent viremia after 1 year of combination antiretroviral therapy.
Loutfy MR, Walmsley SL, Mullin CM, Perez G, Neaton JD; Terry Beirn Community Programs for Clinical Research on AIDS; Canada HIV Trials Network. Loutfy MR, et al. Among authors: neaton jd. J Infect Dis. 2005 Oct 15;192(8):1407-11. doi: 10.1086/466537. Epub 2005 Sep 9. J Infect Dis. 2005. PMID: 16170758
Prevention of mother to child HIV transmission.
Duran AS, Ivalo SA, Hakim A, Masciottra FM, Zlatkes R, Adissi L, Neaton JD, Losso MH. Duran AS, et al. Among authors: neaton jd. Medicina (B Aires). 2006;66(1):24-30. Medicina (B Aires). 2006. PMID: 16555724
Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count>or=300 cells/microL who were assigned to 7.5 MIU interleukin-2.
ESPRIT Research Group; Fox Z, Antunes F, Davey R, Gazzard B, Klimas N, Labriola A, Losso M, Neaton JD, Phillips AN, Ruxrungtham K, Staszewski S, Weiss L, Lundgren JD. ESPRIT Research Group, et al. Among authors: neaton jd. HIV Med. 2007 Mar;8(2):112-23. doi: 10.1111/j.1468-1293.2007.00440.x. HIV Med. 2007. PMID: 17352768 Free article. Clinical Trial.
Risk of cancers during interrupted antiretroviral therapy in the SMART study.
Silverberg MJ, Neuhaus J, Bower M, Gey D, Hatzakis A, Henry K, Hidalgo J, Lourtau L, Neaton JD, Tambussi G, Abrams DI. Silverberg MJ, et al. Among authors: neaton jd. AIDS. 2007 Sep 12;21(14):1957-63. doi: 10.1097/QAD.0b013e3282ed6338. AIDS. 2007. PMID: 17721103 Clinical Trial.
302 results